LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Amfm Independent Evaluation Team: Hanson, K; Goodman, C; Tougher, S; Mann, A; Willey, B; Arnold, F; Ye, Y; Ren, R; Yoder, S (2012)
Publisher: ICF International and London School of Hygiene and Tropical Medicine
Languages: English
Types: Book
Subjects:
The success of malaria control efforts depends on a high level of coverage in the use of effective antimalarials such as artemisinin-based combination therapies (ACTs). Although these anti-malarials have been procured in large amounts by countries, evidence suggests that ACT use still remains far below target levels. In response to this issue, the Affordable Medicines Facility – malaria (AMFm) hosted by the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) was set up. AMFm comprises three key elements: (i) price reductions through negotiations with ACT manufacturers; (ii) a buyer subsidy through a ‘co-payment’ for ACTs at the top of the global supply chain; and (iii) supporting interventions to promote appropriate use of ACTs. Examples of these supporting interventions include training providers and outreach to communities to promote ACT use. All ACTs subsidized through AMFm bear a green leaf logo on their packaging. The four main objectives of AMFm are to: (i) increase ACT affordability; (ii) increase ACT availability; (iii) increase ACT use, including among vulnerable groups; and (iv) “crowd out” oral artemisinin monotherapies, chloroquine and sulfadoxine-pyrimethamine (SP) by increasing the market share for ACTs.

Share - Bookmark

Download from

Funded by projects

  • WT

Cite this article